# EDGAR Filing Document

**Accession Number:** 0001810560
**File Stem:** 0001193125-26-251784
**Filing Date:** 2026-6
**Character Count:** 6581
**Document Hash:** fd0464e4fa4fb7b084cc75297237d09a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-251784.hdr.sgml**: 20260601

**ACCESSION NUMBER**: 0001193125-26-251784

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 33

**CONFORMED PERIOD OF REPORT**: 20260601

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260601

**DATE AS OF CHANGE**: 20260601

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REVELATION BIOSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001810560
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 843898466
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39603
- **FILM NUMBER:** 261052432

**BUSINESS ADDRESS:**
- **STREET 1:** 4660 LAJOLLA VILLAGE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122
- **BUSINESS PHONE:** 650-800-3717

**MAIL ADDRESS:**
- **STREET 1:** 4660 LAJOLLA VILLAGE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Petra Acquisition Inc.
- **DATE OF NAME CHANGE:** 20200423

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** June 01, 2026<br>

------

REVELATION BIOSCIENCES, INC.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-39603 | 84-3898466 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 4660 La Jolla Village Drive<br>Suite 100 |  |  |
| San Diego**,** California |  | 92122 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (650) 800-3717<br>

Not Applicable

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common stock, par value $0.001 per share | REVB | The Nasdaq Stock Market LLC |
| Redeemable warrants, each exercisable for a 1/201,600th share of common stock at an exercise price of $2,318,400 per share | REVBW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 8.01 Other Information.
On June 1, 2026, Revelation Biosciences, Inc. (the "Company") prepared and released an updated corporate presentation made available to the public. The corporate presentation can be found on the Company's website. A copy of the presentation is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

*The information in this Item 8.01 and in Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.*

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [<u>99.1</u>](revb-ex99_1.htm) | [<u>Corporate Presentation, dated June 1, 2026</u>](revb-ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded with the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  |  | **REVELATION BIOSCIENCES, INC.** |
| Date: June 1, 2026 | By:  | */s/ Chester S. Zygmont, III* |
|  |  | **Chester S. Zygmont, III**<br> Chief Financial Officer<br>(principal financial and accounting officer) |

---

------

## Exhibit 99.1

**Exhibit 99.1**

![img220778470_0.jpg](img220778470_0.jpg)

![img220778470_1.jpg](img220778470_1.jpg)

------

![img220778470_2.jpg](img220778470_2.jpg)

![img220778470_3.jpg](img220778470_3.jpg)

------

![img220778470_4.jpg](img220778470_4.jpg)

![img220778470_5.jpg](img220778470_5.jpg)

------

![img220778470_6.jpg](img220778470_6.jpg)

![img220778470_7.jpg](img220778470_7.jpg)

------

![img220778470_8.jpg](img220778470_8.jpg)

![img220778470_9.jpg](img220778470_9.jpg)

------

![img220778470_10.jpg](img220778470_10.jpg)

![img220778470_11.jpg](img220778470_11.jpg)

------

![img220778470_12.jpg](img220778470_12.jpg)

![img220778470_13.jpg](img220778470_13.jpg)

------

![img220778470_14.jpg](img220778470_14.jpg)

![img220778470_15.jpg](img220778470_15.jpg)

------

![img220778470_16.jpg](img220778470_16.jpg)

![img220778470_17.jpg](img220778470_17.jpg)

------

![img220778470_18.jpg](img220778470_18.jpg)

![img220778470_19.jpg](img220778470_19.jpg)

------

![img220778470_20.jpg](img220778470_20.jpg)

![img220778470_21.jpg](img220778470_21.jpg)

------

![img220778470_22.jpg](img220778470_22.jpg)

------